Robert Driscoll

Robert Driscoll Analyst Performance

Senior Vice President, Equity Research at Wedbush

Robert Driscoll is a stock analyst at Wedbush in the healthcare sector, covering 34 publicly traded companies. Over the past year, Robert Driscoll has issued 83 stock ratings, including buy, hold, and sell recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
184 Last 9 Years
Buy Recommendations
79.78% 146 Buy Ratings
Companies Covered
34 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.5%1 ratings
Buy79.2%145 ratings
Hold16.9%31 ratings
Sell3.3%6 ratings

Out of 183 total stock ratings issued by Robert Driscoll at Wedbush, the majority (79.2%) have been Buy recommendations, followed by 16.9% Hold, 3.3% Sell, and 0.5% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
94.1% of companies on NASDAQ
32 companies
NYSE
2.9% of companies on NYSE
1 company
OTCMKTS
2.9% of companies on OTCMKTS
1 company

Robert Driscoll, an analyst at Wedbush, currently covers 34 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
34 companies
100.0%

Robert Driscoll of Wedbush specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
30 companies
88.2%
PHARMACEUTICALS
4 companies
11.8%

About Robert Driscoll

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.
Follow on LinkedIn

Robert Driscoll's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
CG Oncology, Inc. stock logo
CGON
CG Oncology
11/17/2026Boost Price Target$84.78$91.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
11/11/2026Boost Price Target$21.00$57.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
11/11/2026Boost Price Target$11.23$44.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
11/10/2026Upgrade$1.74$6.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
11/10/2026Lower Price Target$23.66$40.00Outperform
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
11/10/2026Lower Price Target$0.87$0.90Neutral
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
11/6/2026Boost Price Target$2.19$12.00Outperform
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
11/6/2026Boost Price Target$16.83$40.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
11/6/2026Lower Price Target$1.67$7.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
11/6/2026Lower Price Target$6.75$20.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
11/6/2026Boost Price Target$74.68$84.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
11/5/2026Lower Price Target$19.32$45.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
11/4/2026Boost Price Target$31.72$63.00Outperform
Geron Corporation stock logo
GERN
Geron
10/28/2026Lower Price Target$0.90$5.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
10/23/2026Lower Price Target$7.45$22.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
10/21/2026Boost Price Target$23.69$49.00Outperform
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
10/2/2026Downgrade$2.92$2.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9/30/2026Reiterated Rating$25.67$43.00Outperform
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
9/28/2026Reiterated Rating$6.52$28.00Outperform
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
9/23/2026Set Price Target$1.24$4.00
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
9/22/2026Downgrade$1.24$1.00Neutral
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
9/14/2026Reiterated Rating$19.41$27.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
9/10/2026Boost Price Target$3.38$8.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
9/10/2026Reiterated Rating$22.01$53.00Outperform
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9/9/2026Reiterated Rating$14.27$27.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8/27/2026Boost Price Target$219.02$225.00Outperform
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
8/27/2026Reiterated Rating$17.80$27.00Outperform
EIKN
Eikon Therapeutics
8/14/2026Lower Price Target$9.86$4.00Underperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8/13/2026Boost Price Target$19.60$42.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
8/13/2026Boost Price Target$9.94$38.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
8/13/2026Lower Price Target$0.68$3.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
8/7/2026Upgrade$12.86$12.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8/6/2026Boost Price Target$198.97$201.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
8/6/2026Boost Price Target$27.92$43.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8/5/2026Boost Price Target$36.11$60.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
8/5/2026Boost Price Target$9.00$12.00Neutral
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
8/3/2026Lower Price Target$16.57$27.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/31/2026Upgrade$5.50$12.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7/28/2026Reiterated Rating$10.15$36.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7/23/2026Boost Price Target$190.09$192.10Outperform
Worse than socialism (Ad)

Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel

Watch Porter Stansberry's full investment broadcast now
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7/2/2026Boost Price Target$185.36$181.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/30/2026Boost Price Target$11.20$9.00Neutral
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
6/12/2026Reiterated Rating$29.45$58.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6/11/2026Reiterated Rating$12.11$37.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
6/2/2026Reiterated Rating$28.94$58.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
6/1/2026Reiterated Rating$163.40Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/1/2026Boost Price Target$9.19$6.00Neutral
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
5/27/2026Lower Price Target$7.91$30.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/14/2026Lower Price Target$19.85$34.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
5/14/2026Boost Price Target$23.72$33.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
5/14/2026Lower Price Target$0.90$6.00Outperform
EIKN
Eikon Therapeutics
5/12/2026Lower Price Target$9.95$5.00Underperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
5/8/2026Boost Price Target$14.96$37.00Outperform
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
5/8/2026Lower Price Target$14.30$36.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
5/7/2026Boost Price Target$144.46$165.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/6/2026Boost Price Target$16.26$40.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
5/5/2026Initiated Coverage$1.76$6.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4/14/2026Boost Price Target$30.82$58.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/14/2026Reiterated Rating$138.88Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
4/13/2026Downgrade$4.77$2.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
4/2/2026Boost Price Target$21.89$41.00Outperform
EIKN
Eikon Therapeutics
3/31/2026Reiterated Rating$10.03$7.00Underperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3/31/2026Reiterated Rating$33.36$52.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3/31/2026Reiterated Rating$0.74$7.00Outperform
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3/17/2026Boost Price Target$2.19$14.00Outperform
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3/17/2026Boost Price Target$6.75$11.00Outperform
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/12/2026Reiterated Rating$4.87$10.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3/11/2026Boost Price Target$14.91$36.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/9/2026Downgrade$21.20$21.50Neutral
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3/6/2026Lower Price Target$8.51$36.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/6/2026Boost Price Target$16.80$19.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/6/2026Downgrade$21.20Hold
EIKN
Eikon Therapeutics
2/26/2026Initiated Coverage$14.89$7.00Underperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/25/2026Boost Price Target$12.02$30.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
2/24/2026Boost Price Target$11.99$11.00Neutral
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2/18/2026Boost Price Target$30.76$52.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2/13/2026Boost Price Target$29.60$53.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2/10/2026Lower Price Target$0.64$7.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
2/4/2026Boost Price Target$7.35$19.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
1/9/2026Reiterated Rating$107.39$147.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12/16/2025Boost Price Target$22.12$37.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
12/11/2025Initiated Coverage$41.74$70.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
12/9/2025Boost Price Target$12.44$34.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
11/14/2025Reiterated Rating$10.68$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
11/6/2025Boost Price Target$59.34$80.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
10/20/2025Upgrade$4.50$18.00Outperform
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
10/20/2025Boost Price Target$19.32$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/17/2025Reiterated Rating$49.68$77.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
9/11/2025Boost Price Target$40.45$77.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Reiterated Rating$3.14$4.00Neutral
Pentagon magnet restrictions take effect January 1, 2027 (Ad)

A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel

Read the full breakdown of the proposed Army rare earth agreement and the company behind it.
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
7/14/2025Initiated Coverage$12.96$27.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6/20/2025Reiterated Rating$6.06$36.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
5/15/2025Reiterated Rating$1.18$4.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
5/9/2025Lower Price Target$0.82$6.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/28/2025Reiterated Rating$41.02$67.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/28/2025Reiterated Rating$1.70$4.00Neutral
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3/20/2025Reiterated Rating$8.04$18.00Outperform
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
3/20/2025Reiterated Rating$7.06$17.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Downgrade$8.30$12.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3/12/2025Reiterated Rating$1.30$8.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/26/2025Reiterated Rating$10.25$32.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2/20/2025Upgrade$8.44Strong-Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2/6/2025Boost Price Target$8.13$36.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
1/24/2025Reiterated Rating$2.22$4.00Neutral